TABLE 2.

Calculated Conversion Ratios for Each Switching Scenario and Subsequent Subgroup Analyses

Scenario and Subgroup Analysis	Calculated Conversion Ratio (Mean ± SD)	p Value
IV to oral suspension (n = 8 switching episodes)	3.04 ± 1.53 (95% CI 1.77–4.32)	0.008
Excluding azoles (n = 7)	3.22 ± 1.56	0.023
Excluding significant CS dose change (n = 3)	3.30 ± 2.10	0.30
Hematocrit normalized (n = 7)	2.76 ± 1.24	0.003
Excluding 3 × ULN ALT (n = 7)	2.66 ± 1.17	0.002
Heart transplant only (n = 7)	3.20 ± 1.58	0.023
IV to capsule (n = 14 switching episodes)	5.18 ± 3.17 (95% CI 3.35–7.00)	0.84
Excluding azoles (n = 0)	NA	NA
Excluding significant CS dose change (n = 5)	6.10 ± 3.13	0.48
Hematocrit normalized (n = 14)	4.87 ± 2.65	0.85
Excluding 3 × ULN ALT (n = 9)	4.32 ± 2.89	0.50
Heart transplant only (n = 12)	5.06 ± 3.24	0.95
Oral suspension to capsule (n = 19 switching episodes)	1.17 ± 0.74 (95% CI 0.82–1.58)	0.32
Excluding azoles (n = 15)	1.10 ± 0.62	0.51
Excluding significant CS dose change (n = 13)	1.05 ± 0.61	0.79
Hematocrit normalized (n = 16)	1.11 ± 0.79	0.60
Excluding 3 × ULN ALT (n = 13)	1.20 ± 0.85	0.42
Heart transplant only (n = 17)	1.00 ± 0.56	0.97

ALT = alanine aminotransferase, CI = confidence interval, CS = corticosteroid, NA = not applicable, SD = standard deviation, ULN = upper limit of normal.